Transdermal Drug Delivery System Market Top Companies, New Technology, Demand and Growth Opportunity Analysis

By -

The growth in the market is expected to be driven by the surge in geriatric population, rise in number of patients suffering from neurovascular disorders and high prevalence of various chronic diseases, across the globe.
Transdermal drug delivery systems are used for various applications such as analgesics, hormone replacement therapy, hypertension, cardiovascular disorders, motion sickness, smoking cessation and others. The hormone replacement therapy category is expected to grow at a CAGR of 10% during the forecast period, since these delivery systems are effective and an easiest way of preventing and managing post-menopausal symptoms.
Request to Get the Sample Pages at:
The use of the transdermal patches is the highest in North America, owing to heavy expenditure by the government on healthcare and supportive reimbursement policies and is further followed by the Europe and APAC, respectively. The market for transdermal drug delivery systems is expected to observe the fastest growth on demand during the forecast period in APAC. This growth in the region is attributable to the improvement in healthcare infrastructures and rise in the healthcare expenditures in developing countries such as China and India, to cater to the unmet medical needs. Further, technological advancements to develop cost-effective technologies in these nations offer a lucrative opportunity for the market growth.

 Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=transdermal-drug-delivery-systems-market

The key players in the transdermal drug delivery systems market are acquiring other players to enter in the new business and to launch advanced products to increase their market share. For instance, In November 2016, Luye Pharma Group Ltd, acquired the transdermal drug delivery systems business from Acino International AG, a leading manufacturer of pharmaceuticals in novel drug delivery forms. The acquisition provided Luye Pharma Group. entry into the transdermal drug delivery systems market.

 Some of the other key players operating in the transdermal drug delivery systems industry include Acrux Limited, Bayer AG, Boehringer Ingelheim Gmbh, Bristol-Myers Squibb Company, Echo Therapeutics, Inc., Endo Pharmaceuticals Inc., Glaxosmithkline Plc, Johnson & Johnson, Mylan N.V. And Novartis Ag.

Comments

Post a Comment

Popular posts from this blog

How the Patient Handling Equipment Market Has Witnessed Substantial Growth in Coming Years?

By -
Image
A report by the United Nations Department of Economic and Social Affairs said that the global population of people in the 60 and above age group is rising rapidly. By the end of 2050, the global share of this age group is expected to grow to 21.1% from 11.7% in 2013. Additionally, the number of people in this age group is predicted to be around 324 million in India, 437 million in China, 58 million in Brazil, and 107 million in the U.S. by 2050. One of the major contributors of the growing elderly population is the increasing life expectancy rate.  Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/patient-handling-equipment-market/report-sample Taking care of the bed-ridden patients or patients with restricted mobility can be taxing for caregivers. They have to perform many tasks, such as lifting, transferring them from one place to another, repositioning, bathing, and dressing a patient. Manual lifting of patients is one of the major risk factors...
Read more

Endoscope Reprocessing Market Size, Business Opportunities and Top Manufacture

By -
Image
 In 2021, the global endoscope reprocessing market was worth around $1,879.9 million, and it is predicted to hit $4,358.1 million by 2030, progressing at a 9.8% CAGR from 2021 to 2030. This is primarily due to the growing preference for minimally invasive treatments, increasing danger of infection by contaminated endoscopes, and rising stringency of the rules governing medical device safety on a global scale. To avoid the complications and extra costs related to the different services offered under contracts with medical equipment manufacturers, end users are increasingly entering into multi-vendor contracts with ISOs. For example, customers may combine all of NovaMed Corporation's services under a single contract, owing to its extensive service management program. With an estimated contribution of $1.0 billion, North America leads the endoscope reprocessing market. This is due to the region's advantageous reimbursement policies, increase in cancer incidence, and demand for les...
Read more

Why are Medical Device Manufacturers Outsourcing Product Manufacturing Processes?

By -
Image
With the rising incidence of chronic diseases and the surging healthcare expenditure of several countries, the demand for medical devices is shooting up across the world. For instance, according to the World Health Organization (WHO), cancer caused the deaths of 9.6 million people in 2018 and it was the second biggest cause of death across the world. Furthermore, the organization found the around 422 million people around the world are living with diabetes, and the disease is responsible for 1.6 million deaths every year.  Additionally, as per an article published in the Cardiac Failure Review, 5.7 million heart failures were reported in the U.S. in 2016, and this number is expected to rise to 8 million by 2030. As a result of the rising incidence of these diseases, many medical device manufacturers are outsourcing the production processes as it helps them reduce cost and save time. Moreover, in order to manage maintenance and quality control, medical device manufacturers are outso...
Read more